Clinical trials: Diffuse Large-Cell Lymphoma
Leukemia, Lymphoma
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005854
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 4 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Non-Hodgkin's Lymphoma
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months.
- Trial name
- NCT01144754
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Chronic Myeloproliferative Disorders, Leukemia
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00993694
- Testing
- chemotherapy, dapsone, medical chart review
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt University
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Diffuse Large B-cell Lymphoma, Relapsed and Refractory
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory…
- Trial name
- NCT06651853
- Testing
- Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Lymphoma, Solid Tumor
Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
RATIONALE: Pemetrexed may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of cancer cells, either…
- Trial name
- NCT00470405
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cachexia, Lymphoma
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053053
- Testing
- Juven, Non-Juven Supplement
- Where
- 250 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Radiation Therapy Oncology Group
Non-GCB/ABC Diffuse Large B-Cell Lymphoma
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients
- Trial name
- NCT04835870
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- 16 sites in China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
This is a multi-center, phase II study to evaluate the efficacy and safety of CTL019 in Chinese adult patients with relapsed or refractory DLBCL.
- Trial name
- NCT04456023
- Testing
- Tisagenlecleucel
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-Cell Lymphoma
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
This is a multicenter, single-arm, prospective study evaluating the efficacy and safety of polatuzumab vedotin and rituximab combined with a reduced-dose regimen of cyclophosphamide, doxorubicin and prednisone (Pola-R-miniCHP) as…
- Trial name
- NCT07908888
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Hospital of Jilin University
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02628405
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Academic and Community Cancer Research United
Non-Hodgkin's Lymphoma
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Trial name
- NCT00115193
- Testing
- pegfilgrastim
- Volunteers
- 77 people
- Sponsor
- Amgen
DLBCL
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
This study evaluate the efficacy of Tafasitamab and Lenalinomide associated to Rituximab in elderly patients with frontline Diffuse Large B-Cell Lymphoma as assessed by the Overall Response Rate (ORR) after 3 cycles of treatment…
- Trial name
- NCT04974216
- Testing
- Tafasitamab, Lenalidomide, Rituximab
- Where
- 20 sites in Belgium, France
- Volunteers
- 71 people
- Sponsor
- The Lymphoma Academic Research Organisation
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Diffuse Large B-cell Lymphoma
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
A clinical study was conducted to evaluate the efficacy and safety of the RCMOP regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large B-cell lymphoma who had incomplete…
- Trial name
- NCT05990985
- Testing
- Mitoxantrone hydrochloride liposome injection, RiTUXimab Injection, Cyclophosphamid
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Lymphoma
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00641381
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diffuse Large B-Cell Lymphoma
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.
- Trial name
- NCT05823701
- Testing
- Chidamide, Azacitidine, obinutuzumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma.
- Trial name
- NCT07124936
- Testing
- HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine
- Where
- 21 sites in China
- Volunteers
- 97 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diffuse Large B Cell Lymphoma
RadiothErapy priMIng for CAR-T
The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
- Trial name
- REMIT (NCT04726787)
- Testing
- Bridging Radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.